Drugs / APL-9796
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06846554 | Apr 2025 → Aug 2027 expected | pulmonary arterial hypertension | Apollo Therapeutics Ltd | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-05 | Apollo Therapeutics Ltd | Apollo Therapeutics marks World Pulmonary Hypertension Day with update on the clinical development of APL-9796 (anti-ZIP12 mAb) for the treatment of Pulmonary Hypertension apollotx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-9796 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846554 ↗ |
| Route | Subcutaneous | “multiple subcutaneous (SC) injections” NCT06846554 ↗ |